JANX:NASDAQJanux Therapeutics, Inc. analysis
Data as of Sep 17, 2026 - not real-time
- Latest price
- $16.25
- Risk: high
- 9/10High risk
Summary
Janux Therapeutics, Inc. trades at $16.25, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 1.8% over the past 30 days. Momentum indicators put RSI at 38.7 (approaching oversold) with MACD reading bearish. Watch $16.04 as support and $20.31 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 123.1% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 51.0%, a beta of 1.09 and a maximum drawdown of 64.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 123.1% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 51.0%, a beta of 1.09 and a maximum drawdown of 64.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top market events
- Janux Therapeutics, Inc. JANX came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of...
- In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or...
- In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 15.12
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 15.12
- Analyst targets imply +123.1% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +123.1% versus the current price
- Negative return on equity of -10.7%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-6.2
ROE-10.70%
ROA-8.80%
Debt/Equity2.26
P/B Ratio1.1
Op. Cash Flow$-41251000
Free Cash Flow$-16392875
Industry P/E30.0
Technical analysis
TrendBullish
RSI38.7
Support$16.04
Resistance$20.31
MA 20$18.31
MA 50$16.91
MA 200$15.12
MACDBearish
VolumeIncreasing
Fear & Greed Index93.77
Valuation
Target Price$36.24
Upside/Downside123.06%
GradeFair
TypeBlend
Risk assessment
Beta1.09
Volatility51.02%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.